

2008 SolvayCARESSM SCHOLARSHIP PROGRAM APPLICATION

Provided as a service from Solvay Pharmaceuticals, Inc. 901 Sawyer Road, Marietta, GA 30062

E-mail: SolvayCARES.Scholarship@solvay.com / Web: SolvayCARES.com

Congratulations!

Congratulations on planning for your future education! As you celebrate this milestone, the organizers of SolvayCARES are eager to learn more about your accomplishments and unique experiences. By sharing your successes, you have an opportunity to inspire others to pursue post-high school education as well.

Legacy of the SolvayCARES Scholarship

In the United States, Solvay Pharmaceuticals has been helping people with cystic fibrosis (CF) manage their health for more than 20 years. Our SolvayCARES program expands this tradition, offering comprehensive support to CF families through nutritional, educational, and financial resources.

Recognizing the financial burdens that exist for many CF families, we developed the SolvayCARES Scholarship to honor young adults with CF as they pursue goals of post-high school education. Since 1993, we have awarded more than 500 scholarships, totaling more than \$1,500,000 in educational funding.

New SolvayCARES Scholarship Opportunities in 2008

We continually seek new ways to support the CF community through the SolvayCARES program. Over the past 15 years, we have been consistently inspired by the outstanding attitudes, accomplishments, and spirit of our scholarship winners. That's why this year we are introducing a new opportunity for SolvayCARES Scholarship winners—a way to earn more scholarship funding while also sharing success stories with people across the country.

Scholarships will continue to be awarded based on applicants' creativity, academic excellence, community involvement, financial need, and ability to serve as a role model for the CF community.

In 2008, **40 SolvayCARES Scholarship winners** will be announced, and each one will receive **\$2500** for use during the upcoming academic year.

New this year, all 40 winners' stories will be posted online at www.SolvayCARESScholarship.com so that people from around the country can vote for the winner they find most inspiring. Please note that winners will have the option to opt out of this part of the program.

The **SolvayCARES "Thriving Student Achiever" Scholarship winner** who receives the most votes will be awarded **\$10,000** in place of the standard \$2500 award.

Good Luck!

As always, the SolvayCARES team is very much looking forward to being inspired by your application to the scholarship program. Good luck to you as you prepare your application and continue your educational journey.



APPLICATION PROCESS

To apply, submit a completed application that is postmarked **no later than June 20, 2008**. Applications postmarked after June 20, 2008, will be ineligible. Only one complete application per student will be accepted. Please be sure to review the application checklist prior to submitting your entry since incomplete applications will not be eligible.

Eligibility Requirements

Previous SolvayCARES Scholarship winners are eligible to reapply upon completion of their current award cycle. There is no limit on the number of times an individual may win a SolvayCARES Scholarship as long as he/she is pursuing postsecondary education. Students pursuing graduate or postdoctoral degrees are eligible and welcome to apply.

This program is designed for applicants of any age who have completed high school or obtained GED certification on or before June 20, 2008. It is not necessary for applicants to currently take CREON® (Pancrelipase Delayed-release Capsules, USP)* or to take CREON® in the future to apply for the scholarship. CREON® use is not a consideration in the winner selection criteria.

Employees of Solvay Pharmaceuticals and their immediate family members are not eligible.

Each applicant must be

- A legal and permanent resident of the United States
- Diagnosed with CF by a physician
- Enrolled in or awaiting acceptance from an accredited institution (eg, college, university, trade, or vocational school) for an educational program during the 2008-2009 academic year (winners will be required to provide proof of enrollment)

SolvayCARES Scholarship Award

From all eligible applications received, 40 winners will be chosen to receive a 1-year \$2500 scholarship for use during the 2008-2009 academic year.

In addition, after submitting an original, signed prescription from his/her physician, each recipient will have the option

to receive a 1-year supply of CREON® and a 1-year supply of nutritional drinks and vitamins. This offer is extended to winners so that they may discuss the option with their primary healthcare provider. Acceptance of the offer to receive either CREON® or nutritional supplements should be based on the discretion and counsel of the winner's primary healthcare provider.

SolvayCARES "THRIVING STUDENT ACHIEVER" SCHOLARSHIP AWARD

In 2008, all 40 winning entries will be posted online for an opportunity to win an additional scholarship. Patients, families, friends, physicians, the CF community, and the general public will have an opportunity to vote for the student who most inspires them based on the submitted essay and creative presentation. The winner receiving the highest number of votes will receive an additional \$7500 for a total award of \$10,000.

*See attached CREON full prescribing information.

2008 SolvayCARESSM SCHOLARSHIP PROGRAM APPLICATION

Provided as a service from Solvay Pharmaceuticals, Inc. 901 Sawyer Road, Marietta, GA 30062

E-mail: SolvayCARES.Scholarship@solvay.com / Web: SolvayCARES.com

STUDENT VERIFICATION AND CONSENT

Please enter my application in the 2008 SolvayCARES Scholarship Program. My signature below confirms that I meet the eligibility requirements outlined in the application package and that the information contained within my submitted application is true and accurate to the best of my knowledge. I have read and accept the scholarship criteria and agree to fulfill the obligations outlined in this application package if I am chosen as a winner. I understand that recipient selection will be at the sole discretion of the judges chosen by Solvay Pharmaceuticals, Inc.

If I am selected as a scholarship recipient, I give permission to Solvay Pharmaceuticals to use all or part of my application, essay, creative presentation, and photograph on the Web (including www.SolvayCARESScholarship.com) or in any publication or program designed to help other people with CF and to use my creative presentation for whatever purpose the organization deems appropriate. I further give permission to send my photograph and announcement to news organizations if I am selected as a winner.

I also give Solvay Pharmaceuticals permission to contact me in the future regarding the SolvayCARES Scholarship and other SolvayCARES updates.

Signature: _____ Date: _____

Parent's or Guardian's Signature (if applicant under 18):

Signature: _____ Date: _____




APPLICATION SUBMISSION

Incomplete applications/applications postmarked after **June 20, 2008**, will NOT be considered.

Prior to submitting your application, please confirm that you have completed in full each of the following portions of the application:

- Student Information (including photo)
- Academic Information
- Extracurricular Involvement
- Essay
- Creative Presentation
- Financial Information (including copies of relevant federal income tax returns)
- Student Verification and Consent



Mail completed application to: **Solvay Pharmaceuticals, Inc.**
ATTN: 2008 SolvayCARES Scholarship Program
901 Sawyer Road
Marietta, GA 30062

If you have questions regarding the scholarship program or the status of your application, you may contact the program's administrators at SolvayCARES.Scholarship@solvay.com

Congratulations on completing your SolvayCARES Scholarship application, and good luck with your educational endeavors!

CREON FULL PRESCRIBING INFORMATION

CREON® 5 MINIMICROSOPHERES® (Pancrelipase Delayed-release Capsules, USP)

500197 Rev Feb 2006

PRESCRIBING INFORMATION DESCRIPTION

CREON® 5 Capsules are orally administered and contain pancrelipase (lipase 5,000 USP Units, protease 18,750 USP Units and amylase 16,600 USP Units per capsule) which is of porcine pancreatic origin. Each CREON 5 Capsule is filled with 124 mg of delayed-release MINIMICROSOPHERES®.

Inactive ingredients include dibutyl phthalate, dimethicone, hydroxypropylmethylcellulose phthalate, light mineral oil and polyethylene glycol. The capsule shells contain gelatin, red iron oxide, titanium dioxide, yellow iron oxide and FD & C blue No. 2. The capsule imprinting ink contains dimethicone, 2-ethoxyethanol, shellac, soya lecithin, and titanium dioxide.

CLINICAL PHARMACOLOGY

The pancreatic enzymes in CREON 5 Capsules are enteric-coated to resist gastric destruction or inactivation. The pancreatic enzymes catalyze the hydrolysis of fats to glycerol and fatty acids, protein into proteoses and derived substances and starch into dextrins and short chain sugars.

INDICATIONS

CREON 5 Capsules are indicated for patients with pancreatic exocrine insufficiency as is often associated with:

- cystic fibrosis
- chronic pancreatitis
- post-pancreatectomy
- post-gastrointestinal bypass surgery (e.g., Billroth II gastroenterostomy)
- ductal obstruction from neoplasm (e.g., of the pancreas or common bile duct)

CONTRAINDICATIONS

CREON 5 Capsules are contraindicated in the early stages of acute pancreatitis or in patients who are known to be hypersensitive to pork protein.

WARNINGS

Should symptoms of hypersensitivity appear, discontinue medication and initiate symptomatic and supportive therapy if necessary.

Strictures in the ileo-cecal region and/or ascending colon have been reported in cystic fibrosis patients treated with high doses of high-potency pancreatic enzyme supplements containing 20,000 or greater USP units of lipase per capsule. The underlying mechanism is unknown, but caution should be exercised when doses in excess of 6,000 USP units lipase per kg per meal fail to resolve symptoms, especially in patients with a history of intestinal complications such as meconium ileus equivalent, short bowel syndrome, surgery or Crohn's disease. If symptoms suggestive of gastrointestinal obstruction occur, the possibility of bowel stricture should be investigated including evaluation of pancreatic enzyme therapy.

PRECAUTIONS

CREON 5 Capsules MINIMICROSOPHERES SHOULD NOT BE CRUSHED OR CHEWED or placed on foods having a pH greater than 5.5. These can dissolve the protective enteric coating resulting in early release of enzymes, irritation of oral mucosa, and/or loss of enzyme activity.

Information for Patients

CREON 5 Capsules are a pancreatic enzyme product prescribed to promote improved digestion of foods, especially fat. The prescribed dosage should be taken with each meal and snack or as directed by the physician. The capsules can be swallowed whole, or the contents poured on soft, bland food. Care should be taken to avoid chewing or crushing of the capsule contents, which can result in early release of enzymes, irritation of oral mucosa, and/or loss of enzyme activity. Patients should maintain adequate fluid intake. The prescribed dose range should not be exceeded without calling your doctor.

The most common adverse reactions involve the stomach and intestine including diarrhea, nausea, vomiting, bloating, constipation, stomach cramps or pain. If these symptoms are persistent, contact your doctor.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term studies in animals have not been performed to evaluate carcinogenic potential.

Pregnancy, Category C

Animal reproduction studies have not been conducted with pancrelipase. It is also not known whether pancrelipase can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. CREON 5 Capsules should be given to a pregnant woman only if clearly needed.

Nursing Mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when CREON 5 Capsules are administered to a nursing mother.

ADVERSE REACTIONS

The most frequently reported adverse reactions to pancreatic enzyme-containing products are gastrointestinal in nature which may include nausea, vomiting, bloating, cramping, constipation or diarrhea. Less frequently, allergic-type reactions have also been observed. Very high doses of pancreatin have been associated with hyperuricosuria and hyperuricemia.

DOSE AND ADMINISTRATION

Clinical experience should dictate initial starting dose. Doses should be taken during meals or snacks, not before or after. Do not take without food.

Adults and Children Over 6 Years Old

Usual initial starting dosage is two to four CREON 5 Capsules per meal or snack.

Children Under 6 Years Old

The exact dosage of CREON 5 Capsules should be selected based on clinical experience for this age group. Patients can be started on one to two capsules per meal or snack.

For cystic fibrosis patients, typical doses are 1,500 - 3,000 USP lipase units/kg/meal. Dosage should be adjusted according to the severity of the disease, control of steatorrhea and maintenance of good nutritional status. Doses in excess of 6,000 USP lipase units/kg/meal are not recommended.

Dose increases, if required, should occur with careful monitoring of body weight and stool fat content. When changing strengths of pancreatic enzyme products, care should be taken to maintain equivalent lipase units for each divided dosage. It is important to ensure adequate hydration of patients at all times while taking pancreatic enzymes.

Where swallowing of capsules is difficult, the capsules may be carefully opened and the MINIMICROSOPHERES added to a small amount of soft food, with a pH less than 5.5. The soft food should be swallowed immediately without chewing and followed with a glass of water or juice to insure swallowing.

HOW SUPPLIED

CREON 5 MINIMICROSOPHERES (Pancrelipase Delayed-release Capsules, USP) are available in a two-piece gelatin capsule (orange opaque top half, blue opaque bottom half) imprinted in white with "SOLVAY" and "1205". Each capsule contains tan-colored delayed-release MINIMICROSOPHERES of pancrelipase supplied in bottles of:

100,.....NDC 0032-1205-01

250,.....NDC 0032-1205-07

CREON 5 Capsules must be stored at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F). [See USP Controlled Room Temperature.] PROTECT FROM MOISTURE. DO NOT REFRIGERATE. Dispense in tight, light-resistant containers. For human consumption only.

Rx only

Manufactured By:
Solvay Pharmaceuticals GmbH,
Hannover, Germany
Marketed by:
Solvay Pharmaceuticals, Inc.
Marietta, GA 30062

500197 Rev Feb 2006

MINIMICROSOPHERES is a registered Trademark of Solvay Pharmaceuticals, Inc.
© 2006 Solvay Pharmaceuticals, Inc.

Rx only

CREON® 10 MINIMICROSOPHERES® (Pancrelipase Delayed-release Capsules, USP)

500198 Rev Feb 2006

PRESCRIBING INFORMATION DESCRIPTION

CREON® 10 Capsules are orally administered and contain pancrelipase (lipase 10,000 USP Units, protease 37,500 USP Units, and amylase 33,200 USP Units per capsule) which is of porcine pancreatic origin. Each CREON 10 Capsule is filled with 249 mg of delayed-release MINIMICROSOPHERES®.

Inactive ingredients include dibutyl phthalate, dimethicone, hydroxypropylmethylcellulose phthalate, light mineral oil and polyethylene glycol. The capsule shells contain black iron oxide, gelatin, red iron oxide, titanium dioxide, and yellow iron oxide. The capsule imprinting ink contains dimethicone, 2-ethoxyethanol, shellac, soya lecithin, and titanium dioxide.

CLINICAL PHARMACOLOGY

The pancreatic enzymes in CREON 10 Capsules are enteric-coated to resist gastric destruction or inactivation. The pancreatic enzymes catalyze the hydrolysis of fats to glycerol and fatty acids, protein into proteoses and derived substances and starch into dextrins and short chain sugars.

INDICATIONS

CREON 10 Capsules are indicated for patients with pancreatic exocrine insufficiency as is often associated with:

- cystic fibrosis
- chronic pancreatitis
- post-pancreatectomy
- post-gastrointestinal bypass surgery (e.g., Billroth II gastroenterostomy)
- ductal obstruction from neoplasm (e.g., of the pancreas or common bile duct)

CONTRAINDICATIONS

CREON 10 Capsules are contraindicated in the early stages of acute pancreatitis or in patients who are known to be hypersensitive to pork protein.

WARNINGS

Should symptoms of hypersensitivity appear, discontinue medication and initiate symptomatic and supportive therapy if necessary.

Strictures in the ileo-cecal region and/or ascending colon have been reported in cystic fibrosis patients treated with high doses of high-potency pancreatic enzyme supplements containing 20,000 or greater USP units of lipase per capsule. The underlying mechanism is unknown, but caution should be exercised when doses in excess of 6,000 USP units lipase per kg per meal fail to resolve symptoms, especially in patients with a history of intestinal complications such as meconium ileus equivalent, short bowel syndrome, surgery or Crohn's disease. If symptoms suggestive of gastrointestinal obstruction occur, the possibility of bowel stricture should be investigated including evaluation of pancreatic enzyme therapy.

PRECAUTIONS

CREON 10 Capsules MINIMICROSOPHERES SHOULD NOT BE CRUSHED OR CHEWED or placed on foods having a pH greater than 5.5. These can dissolve the protective enteric coating resulting in early release of enzymes, irritation of oral mucosa, and/or loss of enzyme activity.

Information for Patients

CREON 10 Capsules are a pancreatic enzyme product prescribed to promote improved digestion of foods, especially fat. The prescribed dosage should be taken with each meal and snack or as directed by the physician. The capsules can be swallowed whole, or the contents poured on soft, bland food. Care should be taken to avoid chewing or crushing of the capsule contents, which can result in early release of enzymes, irritation of oral mucosa, and/or loss of enzyme activity. Patients should maintain adequate fluid intake. The prescribed dose range should not be exceeded without calling your doctor.

The most common adverse reactions involve the stomach and intestine including diarrhea, nausea, vomiting, bloating, constipation, stomach cramps or pain. If these symptoms are persistent, contact your doctor.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term studies in animals have not been performed to evaluate carcinogenic potential.

Pregnancy, Category C

Animal reproduction studies have not been conducted with pancrelipase. It is also not known whether pancrelipase can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. CREON 10 Capsules should be given to a pregnant woman only if clearly needed.

Nursing Mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when CREON 10 Capsules are administered to a nursing mother.

ADVERSE REACTIONS

The most frequently reported adverse reactions to pancreatic enzyme-containing products are gastrointestinal in nature which may include nausea, vomiting, bloating, cramping, constipation or diarrhea. Less frequently, allergic-type reactions have also been observed. Very high doses of pancreatin have been associated with hyperuricosuria and hyperuricemia.

DOSE AND ADMINISTRATION

Clinical experience should dictate initial starting dose. Doses should be taken during meals or snacks, not before or after. Do not take without food.

Adults and Children Over 6 Years Old

Usual initial starting dosage is one to two CREON 10 Capsules per meal or snack.

Children Under 6 Years Old

Usual initial starting dosage is up to one CREON 10 Capsule per meal or snack.

For cystic fibrosis patients, typical doses are 1,500 - 3,000 USP lipase units/kg/meal. Dosage should be adjusted according to the severity of the disease, control of steatorrhea and maintenance of good nutritional status. Doses in excess of 6,000 USP lipase units/kg/meal are not recommended.

Dose increases, if required, should occur with careful monitoring of body weight and stool fat content. When changing strengths of pancreatic enzyme products, care should be taken to maintain equivalent lipase units for each divided dosage. It is important to ensure adequate hydration of patients at all times while taking pancreatic enzymes.

Where swallowing of capsules is difficult, the capsules may be carefully opened and the MINIMICROSOPHERES added to a small amount of soft food, with a pH less than 5.5. The soft food should be swallowed immediately without chewing and followed with a glass of water or juice to insure swallowing.

HOW SUPPLIED

CREON 10 MINIMICROSOPHERES (Pancrelipase Delayed-release Capsules, USP) are available in a two-piece gelatin capsule (brown opaque top half, natural transparent bottom half) imprinted in white with "SOLVAY" and "1210". Each capsule contains tan-colored delayed-release MINIMICROSOPHERES of pancrelipase supplied in bottles of:

100,.....NDC 0032-1210-01

250,.....NDC 0032-1210-07

CREON 10 Capsules must be stored at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F). [See USP Controlled Room Temperature.] PROTECT FROM MOISTURE. DO NOT REFRIGERATE. Dispense in tight, light-resistant containers. For human consumption only.

Manufactured By:

Solvay Pharmaceuticals GmbH,
Hannover, Germany
Marketed by:
Solvay Pharmaceuticals, Inc.
Marietta, GA 30062

500198 Rev Feb 2006

MINIMICROSOPHERES is a registered Trademark of Solvay Pharmaceuticals, Inc.

© 2006 Solvay Pharmaceuticals, Inc.

Rx only

CREON® 20 MINIMICROSOPHERES® (Pancrelipase Delayed-release Capsules, USP)

500199 Rev Feb 2006

PRESCRIBING INFORMATION DESCRIPTION

CREON® 20 Capsules are orally administered and contain pancrelipase (lipase 20,000 USP Units, protease 75,000 USP Units and amylase 66,400 USP Units per capsule) which is of porcine pancreatic origin. Each CREON 20 Capsule is filled with 497 mg of delayed-release MINIMICROSOPHERES®.

Inactive ingredients include dibutyl phthalate, dimethicone, hydroxypropylmethylcellulose phthalate, light mineral oil and polyethylene glycol. The capsule shells contain gelatin, red iron oxide, titanium dioxide and yellow iron oxide. The capsule imprinting ink contains dimethicone, 2-ethoxyethanol, shellac, soya lecithin, and titanium dioxide.

CLINICAL PHARMACOLOGY

The pancreatic enzymes in CREON 20 Capsules are enteric-coated to resist gastric destruction or inactivation. The pancreatic enzymes catalyze the hydrolysis of fats to glycerol and fatty acids, protein into proteoses and derived substances and starch into dextrins and short chain sugars.

INDICATIONS

CREON 20 Capsules are indicated for patients with pancreatic exocrine insufficiency as is often associated with:

- cystic fibrosis
- chronic pancreatitis
- post-pancreatectomy
- post-gastrointestinal bypass surgery (e.g., Billroth II gastroenterostomy)
- ductal obstruction from neoplasm (e.g., of the pancreas or common bile duct)

CONTRAINDICATIONS

CREON 20 Capsules are contraindicated in the early stages of acute pancreatitis or in patients who are known to be hypersensitive to pork protein.

WARNINGS

Should symptoms of hypersensitivity appear, discontinue medication and initiate symptomatic and supportive therapy if necessary.

Strictures in the ileo-cecal region and/or ascending colon have been reported in cystic fibrosis patients treated with high doses of high-potency pancreatic enzyme supplements containing 20,000 or greater USP units of lipase per capsule. The underlying mechanism is unknown, but caution should be exercised when doses in excess of 6,000 USP units lipase per kg per meal fail to resolve symptoms, especially in patients with a history of intestinal complications such as meconium ileus equivalent, short bowel syndrome, surgery or Crohn's disease. If symptoms suggestive of gastrointestinal obstruction occur, the possibility of bowel stricture should be investigated including evaluation of pancreatic enzyme therapy.

PRECAUTIONS

CREON 20 Capsules MINIMICROSOPHERES SHOULD NOT BE CRUSHED OR CHEWED or placed on foods having a pH greater than 5.5. These can dissolve the protective enteric coating resulting in early release of enzymes, irritation of oral mucosa, and/or loss of enzyme activity.

Information for Patients

CREON 20 Capsules are a pancreatic enzyme product prescribed to promote improved digestion of foods, especially fat. The prescribed dosage should be taken with each meal and snack or as directed by the physician. The capsules can be swallowed whole, or the contents poured on soft, bland food. Care should be taken to avoid chewing or crushing of the capsule contents, which can result in early release of enzymes, irritation of oral mucosa, and/or loss of enzyme activity. Patients should maintain adequate fluid intake. The prescribed dose range should not be exceeded without calling your doctor.

The most common adverse reactions involve the stomach and intestine including diarrhea, nausea, vomiting, bloating, constipation, stomach cramps or pain. If these symptoms are persistent, contact your doctor.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term studies in animals have not been performed to evaluate carcinogenic potential.

Pregnancy, Category C

Animal reproduction studies have not been conducted with pancrelipase. It is also not known whether pancrelipase can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. CREON 20 Capsules should be given to a pregnant woman only if clearly needed.

Nursing Mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when CREON 20 Capsules are administered to a nursing mother.

ADVERSE REACTIONS

The most frequently reported adverse reactions to pancreatic enzyme-containing products are gastrointestinal in nature which may include nausea, vomiting, bloating, cramping, constipation or diarrhea. Less frequently, allergic-type reactions have also been observed. Very high doses of pancreatin have been associated with hyperuricosuria and hyperuricemia.

DOSE AND ADMINISTRATION

Clinical experience should dictate initial starting dose. Doses should be taken during meals or snacks, not before or after. Do not take without food.

Adults and Children Over 6 Years Old

Usual initial starting dosage is one CREON 20 Capsule per meal or snack.

Children Under 6 Years Old

The exact dosage of CREON 20 Capsules should be selected based on clinical experience for this age group.

For cystic fibrosis patients, typical doses are 1,500 - 3,000 USP lipase units/kg/meal. Dosage should be adjusted according to the severity of the disease, control of steatorrhea and maintenance of good nutritional status. Doses in excess of 6,000 USP lipase units/kg/meal are not recommended.

Dose increases, if required, should occur with careful monitoring of body weight and stool fat content. When changing strengths of pancreatic enzyme products, care should be taken to maintain equivalent lipase units for each divided dosage. It is important to ensure adequate hydration of patients at all times while taking pancreatic enzymes.

Where swallowing of capsules is difficult, the capsules may be carefully opened and the MINIMICROSOPHERES added to a small amount of soft food, with a pH less than 5.5. The soft food should be swallowed immediately without chewing and followed with a glass of water or juice to insure swallowing.

HOW SUPPLIED

CREON 20 MINIMICROSOPHERES (Pancrelipase Delayed-release Capsules, USP) are available in a two-piece gelatin capsule (orange opaque top half, natural transparent bottom half) imprinted in white with "SOLVAY" and "1220". Each capsule contains tan-colored delayed-release MINIMICROSOPHERES of pancrelipase supplied in bottles of:

100,.....NDC 0032-1220-01

250,.....NDC 0032-1220-07

CREON 20 Capsules must be stored at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F). [See USP Controlled Room Temperature.] PROTECT FROM MOISTURE. DO NOT REFRIGERATE. Dispense in tight, light-resistant containers. For human consumption only.

Manufactured By:

Solvay Pharmaceuticals GmbH,
Hannover, Germany
Marketed by:
Solvay Pharmaceuticals, Inc.
Marietta, GA 30062

500199 Rev Feb 2006

MINIMICROSOPHERES is a registered Trademark of Solvay Pharmaceuticals, Inc.

© 2006 Solvay Pharmaceuticals, Inc.

Rx only

2008 SolvayCARESSM SCHOLARSHIP PROGRAM APPLICATION

Provided as a service from Solvay Pharmaceuticals, Inc. 901 Sawyer Road, Marietta, GA 30062

E-mail: SolvayCARES.Scholarship@solvay.com / Web: SolvayCARES.com